Dolby Laboratories, Inc.
Financial highlights
| Metric | FY 09/26/25 | FY 09/27/24 | FY 09/29/23 | FY 09/30/22 | FY 09/24/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B |
| Cost of revenue | $160.1M | $140.5M | $152.6M | $141.4M | $130.0M |
| Gross profit | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B |
| Research and development | $261.8M | $263.7M | $271.5M | $261.2M | $253.6M |
| Operating expenses | $924.0M | $874.9M | $931.4M | $905.8M | $806.8M |
| Operating income | $265.0M | $258.3M | $215.8M | $206.6M | $344.4M |
| Interest expense | — | — | — | $394,000 | $479,000 |
| Pretax income | $303.5M | $312.5M | $250.1M | $215.3M | $354.5M |
| Income tax expense | $47.0M | $48.2M | $48.4M | $31.4M | $36.7M |
| Net income | $255.0M | $261.8M | $200.7M | $184.1M | $310.2M |
| Balance Sheet | |||||
| Cash and equivalents | $701.9M | $482.0M | $745.4M | $620.1M | $1.2B |
| Current assets | $1.4B | $1.2B | $1.5B | $1.3B | $1.8B |
| Total assets | $3.2B | $3.1B | $3.0B | $2.7B | $3.1B |
| Current liabilities | $437.8M | $417.8M | $422.2M | $277.5M | $315.7M |
| Total liabilities | $595.8M | $623.0M | $607.6M | $438.5M | $501.5M |
| Stockholders' equity | $2.6B | $2.5B | $2.4B | $2.2B | $2.6B |
| Cash Flow Statement | |||||
| Cash from operations | $472.2M | $327.3M | $367.1M | $318.6M | $447.8M |
| Depreciation and amortization | $42.5M | $42.4M | $54.0M | $59.5M | $66.4M |
| Stock-based compensation | $128.5M | $119.8M | $118.5M | $114.9M | $99.7M |
| Capital expenditure | $36.3M | $30.0M | $30.3M | $47.9M | $54.5M |
| Free cash flow | $435.9M | $297.2M | $336.7M | $270.6M | $393.3M |
| Dividends paid | $126.6M | $114.6M | $103.4M | $100.1M | $89.2M |
| Share repurchases | $125.0M | $160.0M | $149.3M | $530.5M | $245.9M |
Shares outstanding 94.6M · Free float 25.4%
Annual filing data through FY ended September 26, 2025; float as of July 12, 2026.